Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy was written by Lounsbury, Nicole;Mateo, George;Jones, Brielle;Papaiahgari, Srinivas;Thimmulappa, Rajash K.;Teijaro, Christiana;Gordon, John;Korzekwa, Kenneth;Ye, Min;Allaway, Graham;Abou-Gharbia, Magid;Biswal, Shyam;Childers, Wayne. And the article was included in Bioorganic & Medicinal Chemistry in 2015.Recommanded Product: 2-(Trifluoromethyl)nicotinaldehyde This article mentions the following:
Nrf2 activators represent a good drug target for designing agents to treat diseases associated with oxidative stress. Building upon previous work, we designed and prepared a series of heterocyclic chalcone-based Nrf2 activators with reduced lipophilicity and, in some cases, greater in vitro potency compared to the resp. carbocyclic scaffold. These changes resulted in enhanced oral bioavailability and a superior pharmacodynamic effect in vivo. In the experiment, the researchers used many compounds, for example, 2-(Trifluoromethyl)nicotinaldehyde (cas: 116308-35-1Recommanded Product: 2-(Trifluoromethyl)nicotinaldehyde).
2-(Trifluoromethyl)nicotinaldehyde (cas: 116308-35-1) belongs to pyridine derivatives. The pyridine ring occurs in many important compounds, including agrochemicals, pharmaceuticals, and vitamins. Many analogues of pyridine are known where N is replaced by other heteroatoms . Substitution of one C–H in pyridine with a second N gives rise to the diazine heterocycles (C4H4N2), with the names pyridazine, pyrimidine, and pyrazine.Recommanded Product: 2-(Trifluoromethyl)nicotinaldehyde